Benzphetamine (Didrex) is an anorectic drug marketed under this brand in the USA by Pharmacia. Benzphetamine is used as a short term adjunct in management of exogenous obesity. It is closely related to amphetamine.
Orlistat (marketed as a prescription under the trade name Xenical by Roche in most countries, or over-the-counter as Alli by GlaxoSmithKline) in the United States, also known as tetrahydrolipstatin, is a drug designed to treat obesity. Its primary function is preventing the absorption of fats from the human diet, thereby reducing caloric intake. It is intended for use in conjunction with a physician-supervised reduced-calorie diet.
2,4-Dinitrophenol (DNP), C6H4N2O5, is a cellular metabolic poison. It uncouples oxidative phosphorylation by carrying protons across the mitochondrial membrane, leading to a rapid consumption of energy without generation of ATP. Dinitrophenols as a class of compounds, of which there are six members, do not occur naturally but are all manufactured compounds.
Anti-obesity medication or weight loss drugs refer to all pharmacological agents that reduce or control weight. These drugs alter one of the fundamental processes of the human body, weight regulation, by either altering appetite, metabolism, or absorption of calories. It is common for them to be tried and if there is little or no benefit from them to discontinue treatment. The main treatment modalities for overweight and obesity are dieting and physical exercise.
Sibutramine, usually available as sibutramine hydrochloride monohydrate, is an orally administered agent for the treatment of obesity, as an appetite suppressant. Serious concerns are being expressed about its safety and has been suspended from use in the UK and EU. It is also under review by the FDA and the European Medicines Agency. It is a centrally-acting serotonin-norepinephrine reuptake inhibitor structurally related to amphetamines, although its mechanism of action is distinct.
Oleoyl-estrone (OE) is a fatty acid ester of estrone. It is a naturally circulating hormone in animals including humans. It was first reported in 1996 to cause a body fat loss effect in rats in the International Journal of Obesity and Related Metabolic Disorders. The animal research has all been conducted by the Nitrogen-Obesity Research Group of the University of Barcelona.
Dirlotapide is a drug used to treat obesity in dogs. It is manufactured by Pfizer and marketed as Slentrol. It works as a selective microsomal triglyceride transfer protein inhibitor. This blocks the assembly and release of lipoproteins into the bloodstream, thereby reducing fat absorption. It also elicits a satiety signal from lipid-filled cells lining the intestine. It is supplied as an oral solution. It is not intended for use in humans, cats, or parrots. On January 5 2007, the U.S.
Benfluorex is an anorectic and hypolipidemic agent. Clinical studies have shown it may improve glycemic control and decrease insulin resistance in people with poorly controlled type 2 diabetes; it is marketed in France as an adjuvant antidiabetic.
Tesofensine (NS2330) is a serotonin-noradrenaline-dopamine reuptake inhibitor from the phenyltropane family of drugs, which is being developed for the treatment of obesity. The right to develop and market tesofensine is held by NeuroSearch, a Danish pharmaceutical company.
Lorcaserin (APD-356) is a serotonergic weight-loss drug developed by Arena Pharmaceuticals. As of December 22, 2009 an NDA has been submitted to the FDA in the United States and lorcaserin is pending approval.
Cetilistat is a drug designed to treat obesity. It acts in the same way as the older drug orlistat (Xenical) by inhibiting pancreatic lipase, an enzyme that breaks down triglycerides in the intestine. Without this enzyme, triglycerides from the diet are prevented from being hydrolyzed into absorbable free fatty acids and are excreted undigested.